Press Releases
Press Releases
-
Rezolute Reports First Quarter Fiscal 2022 Financial Results and Highlights Recent Company Progress
-
Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent Registered Direct Offering
-
Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering
-
Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE 2021
-
Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress
-
Rezolute Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism
-
Rezolute to Participate in Upcoming Virtual Healthcare Conferences
-
Rezolute Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolute’s Oral PKI for Treatment of DME
-
Rezolute to Participate in Upcoming Virtual Healthcare Conferences
-
Rezolute Added to Russell Microcap® Index
